Becton, Dickinson and (BDX) versus AngioDynamics (NASDAQ:ANGO) Head to Head Contrast
Becton, Dickinson and (NYSE: BDX) and AngioDynamics (NASDAQ:ANGO) are both medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their valuation, earnings, institutional ownership, profitabiliy, risk, dividends and analyst recommendations.
Volatility & Risk
Becton, Dickinson and has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, AngioDynamics has a beta of 1.15, suggesting that its share price is 15% more volatile than the S&P 500.
Valuation and Earnings
This table compares Becton, Dickinson and and AngioDynamics’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Becton, Dickinson and||$12.32 billion||3.40||$3.20 billion||$3.50||56.18|
|AngioDynamics||$349.64 million||1.73||$52.89 million||$0.19||86.64|
Becton, Dickinson and has higher revenue and earnings than AngioDynamics. Becton, Dickinson and is trading at a lower price-to-earnings ratio than AngioDynamics, indicating that it is currently the more affordable of the two stocks.
Insider & Institutional Ownership
75.7% of Becton, Dickinson and shares are owned by institutional investors. Comparatively, 85.8% of AngioDynamics shares are owned by institutional investors. 1.4% of Becton, Dickinson and shares are owned by company insiders. Comparatively, 1.9% of AngioDynamics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
This table compares Becton, Dickinson and and AngioDynamics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Becton, Dickinson and||6.25%||22.53%||7.25%|
Becton, Dickinson and pays an annual dividend of $2.92 per share and has a dividend yield of 1.5%. AngioDynamics does not pay a dividend. Becton, Dickinson and pays out 83.4% of its earnings in the form of a dividend, suggesting it may not have sufficient earnings to cover its dividend payment in the future. AngioDynamics has raised its dividend for 45 consecutive years.
This is a summary of current ratings and recommmendations for Becton, Dickinson and and AngioDynamics, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Becton, Dickinson and||1||3||6||1||2.64|
Becton, Dickinson and currently has a consensus target price of $191.91, suggesting a potential downside of 2.40%. AngioDynamics has a consensus target price of $18.40, suggesting a potential upside of 11.79%. Given AngioDynamics’ higher possible upside, analysts clearly believe AngioDynamics is more favorable than Becton, Dickinson and.
Becton, Dickinson and beats AngioDynamics on 11 of the 18 factors compared between the two stocks.
About Becton, Dickinson and
Becton, Dickinson and Company (BD) is a global medical technology company engaged in the development, manufacture and sale of a range of medical supplies, devices, laboratory equipment and diagnostic products. The Company operates through two segments: BD Medical and BD Life Sciences. The BD Medical segment produces an array of medical technologies and devices that are used to help improve healthcare delivery in a range of settings. BD Medical consists of various business units, including diabetes care, medication and procedural solutions, medication management solutions and pharmaceutical systems. The BD Life Sciences segment provides products for the safe collection and transport of diagnostics specimens, and instruments and reagent systems to detect a range of infectious diseases, healthcare-associated infections and cancers. The Company’s BD Life Sciences segment consists of various business units, including preanalytical systems, diagnostic systems and biosciences.
AngioDynamics, Inc. designs, manufactures and sells a range of medical, surgical and diagnostic devices used by professional healthcare providers for vascular access, for the treatment of peripheral vascular disease and for use in oncology and surgical settings. The Company’s devices are used in minimally invasive, image-guided procedures. The Company offers products within three product groupings: Peripheral Vascular, Vascular Access and Oncology/Surgery. The Company’s Peripheral Vascular products include Fluid Management, Venous, Thrombus Management, as well as other core products. The Company’s BioFlo products incorporate Endexo Technology into the manufacturing and design of its Vascular Access products. Its Oncology/Surgery product offerings include its Microwave Ablation products, Radiofrequency Ablation (RFA) and its NanoKnife product lines.
Receive News & Stock Ratings for Becton Dickinson and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Becton Dickinson and Company and related stocks with our FREE daily email newsletter.